B-Cell-Depleting Therapies in C3 Glomerulopathy and Primary Immune-Complex Membranoproliferative Glomerulonephritis as a Treatment Option (KIDNEY WEEK 2026) - Oct 2, 2026 - Abstract #SA-PO0733; Pres time: Oct 24, 2026; 10:00 AM - 12:00 PM; Location: Exhibit Hall A, Convention Center; "Case Description We have conducted a multi-center, retrospective case series of 8 C3G/pIC-MPGN patients treated with rituximab (RTX) from 2015 to 2025...Given the small sample size larger prospective studies are needed to better characterize the renal response. With the expanding landscape of B cell directed therapies, antibody depletion in C3G and pIC-MPGN warrants renewed investigation as a potential therapeutic strategy."
Complement-mediated Rare Disorders • Glomerulonephritis • Lupus Nephritis • Nephrology • Renal Disease
|
|
Maja Gunkel; Lucas Kuehne; Benedikt Kolbrink; Federica Zotta; Marina Vivarelli; Roland Schmitt; Paul T. Brinkkoetter; Tobias B. Huber; Tilo Freiwald
|